**Heterozygous and homozygous variants in *STX1A* cause a neurodevelopmental disorder with or without epilepsy**

Johannes Luppe, Heinrich Sticht, François Lecoquierre, Alice Goldenberg, Kathleen Gorman, Ben Molloy, Emanuele Agolini, Antonio Novelli, Silvana Briuglia, Outi Kuismin, Carlo Marcelis, Antonio Vitobello, Anne-Sophie Denommé-Pichon, Sophie Julia, Johannes R. Lemke, Rami Abou Jamra, Konrad Platzer

**Content**

[Figure S1. Pedigree of the family of Individuals 1 and 2. 2](#_Toc101275967)

[Table S1. Detailed phenotypic overview of all individuals with rare variants in STX1A 3](#_Toc101275968)

[Table S2. *In silico* prediction of splice variant in *STX1A* 4](#_Toc101275969)

[Table S3. *In silico* prediction of missense and inframe deletion variants in *STX1A* 5](#_Toc101275970)

[References 6](#_Toc101275971)

**Disclaimer:** due to medRxiv policy, all information has been removed that would allow the patient / study participant or their family, friends or neighbors to identify them (e.g., age, precise location, date of hospital admission, family relationships, past medical history, etc).

Figure S1. Pedigree of the family of Individuals 1 and 2. [removed medRxiv policy]

# Table S1. Detailed phenotypic overview of all individuals with rare variants in STX1A

Provided as a separate Excel-file. [not provided due to medRxiv policy]

# **Table S2.** *In silico* prediction of splice variant in *STX1A*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ind.** | **Genomic position (hg19)** | **Variant****NM\_004603.3** | **CADD-v6**1 | **SpliceAI**2 | **MaxEntScan**3 | **NNSPLICE**4 | **Nucleotide conservation** | **gnomAD**5 |
| 1, 2 | chr7:73118754 | c.284-1G>A, p.? | 35 | 0.95 | 1 | 1 | high | 0 |

Color code represents the probability of the variant to be damaging; red: high

# **Table S3.** *In silico* prediction of missense and inframe deletion variants in *STX1A*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ind.** | **Genomic position (hg19)** | **Variant****NM\_004603.3** | **CADD-v6**1 | **REVEL**6 | **Mutation Taster**7 | **M-CAP 1.3**8 | **Polyphen 2 v2.2.2**9 | **AA conservation** | **gnomAD**5 |
| 3, 4 | chr7:73118509 | c.435C>G,p.(Cys145Trp) | 29.2 | 0.547(LDC) | D | 0.109(PoP) | PrD | high | 0 |
| 5 | chr7:73117299 | c.554C>G,p.(Ser185Cys) | 24.9 | 0.301(MDC) | D | 0.032(PoP) | B | high | 0 |
| 6 | chr7:73117183\_73117185del | c.668\_670delTGG,p.(Val223del) | 22.1 | NA | NA | NA | NA | high | 0 |
| 7 | chr7:73117176 | c.677A>G,p.(Gln226Arg) | 32 | 0.723(LDC) | D | 0.328(PoP) | PrD | high | 0 |
| 8 | chr7:73115125\_73115127del | c.722\_724delTAG,p.(Val241del) | 20.4 | NA | NA | NA | NA | high | 0 |
| (55498)11 | chr7:73119527 | c.236T>G,p.(Met79Arg) | 23.8 | 0.238(MDC) | D | 0.021(LB) | B | high | 0 |

Color code represents the probability of the variant to be damaging; red: high; orange: medium; green: low; LDC = likely disease causing; LDC = maybe disease causing; D = Deleterious; PoP = Possibly Pathogenic; PrD = Probably Damaging; B = Benign; LB = likely benign; NA = not available

# References

1. Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. *Genome Med*. 2021;13(1):31. doi:10.1186/s13073-021-00835-9

2. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24. doi:10.1016/j.cell.2018.12.015

3. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol*. 2004;11(2-3):377-394. doi:10.1089/1066527041410418

4. Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. *Nucleic Acids Res*. 2014;42(22):13534-13544. doi:10.1093/nar/gku1206

5. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7

6. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *The American Journal of Human Genetics*. 2016;99(4):877-885. doi:10.1016/j.ajhg.2016.08.016

7. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods*. 2010;7(8):575-576. doi:10.1038/nmeth0810-575

8. Jagadeesh KA, Wenger AM, Berger MJ, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat Genet*. 2016;48(12):1581-1586. doi:10.1038/ng.3703

9. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet*. 2013;Chapter 7:Unit7.20. doi:10.1002/0471142905.hg0720s76

10. Cooper GM, Stone EA, Asimenos G, et al. Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res*. 2005;15(7):901-913. doi:10.1101/gr.3577405

11. Kaplanis J, Samocha KE, Wiel L, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. *Nature*. 2020;586(7831):757-762. doi:10.1038/s41586-020-2832-5